Скрининг на инфекцию перед началом операции " Окрулизумб " у пациентов с множественным склерозом (MS): Конструктивная клиническая рекомендация, основанная на измененном консенсусе " Делфи " от имени иранской группы по инфекционным заболеваниям.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paybast Sepideh, Abutorabi-Zarchi Marzie, Ashtari Fereshteh, Baghbanian Seyyed Mohammad, Moghadam Nahid Beladi, Ebadi Zahra, Eidi Atefeh, Ghaffari Mehran, Langroodi Hamidreza Ghalyanchi, Heidari Hora, Hosseini Samaneh, Kamali Hoda, Majdinasab Nastaran, Mehrabi Farzad, Nahayati Mohammad Ali, Navardi Samira, Nikseresht Alireza, Poursadeghfard Maryam, Razazian Nazanin, Sahraian Mohammad Ali, Nezhad Vahid Shaygan, Haddadi Azar, Esmailpour Negin, Abdehagh Mohammad, Iranshahi Majid, Azimi Amir Reza
Аннотация
Оригинал публикации
Infection screening prior to Ocrelizumb initiation in patients with Multiple Sclerosis (MS): Concise clinical recommendation based on a modified Delphi consensus on behalf of the Iranian MS -infectious disease group.
Recent scientific literature has addressed the risk of infection associated with ocrelizumab in patients with multiple sclerosis (PwMS). To assist Iranian physicians with decision-making about these risks, a modified Delphi consensus process was conducted. A panel of experts, including MS experts, infectious disease specialists, and gastrointestinal specialists, created clinically relevant, evidence-based recommendations. These recommendations addressed the screening and management strategies for the early identification of tuberculosis, varicella-zoster virus infection, hepatitis B and C virus infection, human immunodeficiency virus infection, secondary hypogammaglobulinemia, vaccination, and required laboratory tests before ocrelizumab infusion in PwMS scheduled to start ocrelizumab. In total, the panel recommended 67 statements to be considered in daily practice for screening before starting ocrelizumab, prophylaxis where appropriate, monitoring, and early treatment of infections in PwMS treated with ocrelizumab.